Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of GHRP-6 and Tesamorelin — mechanism, side effects, legal status, and pricing.
GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) growth hormone secretagogue and ghrelin receptor agonist. Developed by Bowers and Momany and first described in 1984, it was the first synthetic GHRP characterized and is defined by its pronounced appetite-stimulating effect — the strongest of any clinically studied GHRP. It has never been approved by the FDA or any regulatory agency and remains a research-only compound used off-label in the grey market.
Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.
GHRP-6
Tesamorelin
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
GHRP-6
Tesamorelin
COA corpus from Disclosed Labs — independently tested batches only.
GHRP-6
13
COAs
99.4%
Avg purity
4
Labs
Tesamorelin
175
COAs
99.5%
Avg purity
14
Labs
GHRP-6 and Tesamorelin are both among peptides under FDA review for the Category 1 (503A) list; if added, they would require a prescription to be compounded by registered 503A/503B pharmacies — they are not yet authorized. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
GHRP-6 was first characterized by Bowers, Momany, Reynolds, and Hong in Endocrinology (1984, PMID 6714155), establishing it as the first synthetic peptide to specifically release GH via a non-GHRH mechanism — a key tool in the later discovery of the ghrelin receptor. Ghigo et al. (European Journal of Endocrinology, 1997, PMID 9186261) reviewed the GHRP class and confirmed GH, ACTH/cortisol, and prolactin co-stimulation in humans. Berlanga et al. (Clinical Science, 2007, PMID 16989643) demonstrated ~78% infarct-mass reduction in a porcine myocardial infarction model via antioxidant mechanisms, and Berlanga-Acosta et al. (Clinical Medicine Insights: Cardiology, 2017, PMID 28469491) reviewed the cytoprotective GHRP literature across cardiac, neuronal, and hepatic tissues. GHRP-6 has never been approved for any clinical indication; its intense appetite stimulation and cortisol/prolactin co-release limit its clinical utility compared with ipamorelin.
Key references
FDA approval (NDA 022505) was based on two Phase 3 trials reported by Falutz et al. (NEJM, 2007; PMID 18057338) and the pooled 52-week safety extension, showing ~15-18% reduction in visceral adipose tissue with improved triglycerides in HIV patients with abdominal fat accumulation. Stanley et al. (JAMA, 2014; PMID 25038357) demonstrated concurrent reductions in visceral and liver fat (NAFLD). Baker et al. (Arch Neurol, 2012; PMID 22869065) reported favorable effects on executive function in older adults with and without mild cognitive impairment at 1 mg/day for 20 weeks — note this cognition signal was in MCI / healthy older adults, not specifically APOE4-positive individuals. Current label dose is 1.4 mg SubQ daily (Egrifta SV); legacy Egrifta used 2 mg/day. Off-label use for general body composition in non-HIV populations is common but outside the FDA label.
GHRP-6 and Tesamorelin are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs